#imvt
Latest news and interesting information about imvt.
H.C. Wainwright Raises Immunovant Target to $40
H.C. Wainwright raises Immunovant price target to $40 from $35 after positive Phase 2 RA data, maintains Buy rating.
Immunovant director sells $192,000 in shares
Immunovant director Atul Pande sold $192,000 worth of shares. Stock up 147% in past year, but company remains unprofitable.
Immunovant Stock Hits 52-Week High at $30.27
Immunovant stock hits 52-week high at $30.27 with 82% annual gain. Market cap $5.35B. Strong liquidity and investor confidence.
Immunovant stock jumps 20% on RA trial
Immunovant stock jumps 20% after positive rheumatoid arthritis trial data for IMVT-1402.
...